Anne Wojcicki, 23andMe CEO (Jordan Vonderhaar/Bloomberg via Getty Images)

November 11, 2024 06:44 PM EST

23andMe to shut down its therapeutics division

Shelby Livingston

Health tech correspondent

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Updated: White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain

Lack of detail in Trump's drug price plan raises more questions than answers

Pharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise

Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

Roche could rethink $50B US expansion plan if new policies 'harm' operations

PBM overhaul and drug price negotiations make the cut in Republicans' tax bill